Detection of Drug Interactions Involving Radiopharmaceuticals: A Professional Responsibility of the Clinical Pharmacist
Detection of Drug Interactions Involving Radiopharmaceuticals: A Professional Responsibility of the Clinical Pharmacist
复制标题
涉及放射性药物的药物相互作用的检测：临床药剂师的专业责任
DOI：
10.1177/089719008900200506
复制
发表时间：
1989
影响因子：
1.3
通讯作者：
S. M. Shaw
中科院分区：
文献类型：
--
作者：
D. Laven;S. M. Shaw
放射性药物是核医学中用于诊断和在某种程度上用于治疗疾病的放射性药物。有相当多的证据表明，由于治疗药物的共同施用以及某些疾病状态、营养状况和其他因素，放射性药物的生物路线可能发生改变。改变生物路线可能会降低诊断测试的有效性或提供误导性信息。虽然对改变的生物分布问题进行回顾性鉴定可能有所帮助，但前瞻性检测更可取，并且可以由医院的药剂师实现。虽然大多数药物-放射性药物相互作用是不利的，但一些核医学程序使用药物干预来提高测试的诊断效果。此外，核医学程序可用于监测治疗方案的结果或帮助确定研究药物的药理学效应。虽然没有涵盖该领域的全部范围，但本章中的材料旨在介绍与药物-放射性药物相互作用相关的问题和机会，并激励药剂师为核医学提供临床药学服务。
Radiopharmaceuticals are radioactive drugs used in nuclear medicine for diagnosis and, to some degree, for the treatment of disease. Considerable evidence exists in regard to the potential for altered biorouting of radiopharmaceuticals resulting from the coadministration of therapeutic drugs, as well as from certain disease states, nutritional conditions, and other factors. Altered biorouting may reduce the usefulness of the diagnostic test or provide misleading information. While retrospective identification of an altered biodistribution problem can be helpful, prospective detection is more desirable and can be achieved by a hospital-based pharmacist. Although most drug-radiopharmaceutical interactions are not beneficial, some nuclear medicine procedures are conducted using drug intervention to enhance the diagnostic efficacy of the test. Also, nuclear medicine procedures may be used to monitor the outcome of a therapeutic regimen or to aid in determining the pharmacologic effect of an investigation drug. While not covering the full scope of the area, the material in this chapter is intended to provide an introduction to the problems and opportunities associated with drug-radiopharmaceutical interactions and to stimulate pharmacists to provide clinical pharmacy services to nuclear medicine.